Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.

ABSTRACT:

Background

Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in everyday clinical practice.

Objectives

To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinical response and treatment discontinuation in patients with moderate-to-severe PsA, using real-world data from the Italian Group for the Study of Early Arthritis (GISEA) registry.

Design

This longitudinal retrospective study included PsA patients treated with SECU, spanning from May 2016 to November 2023.

Methods

Data from 1045 PsA patients, including 783 with peripheral-only PsA (perPsA) and

SUBMITTER: Lopalco G 

PROVIDER: S-EPMC11783553 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature